文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

纳武利尤单抗辅助治疗对比观察用于已切除非小细胞肺癌的随机临床试验

Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

这项开放标签3期随机试验纳入已切除、无EGFR/ALK敏感突变的非小细胞肺癌患者,比较辅助纳武利尤单抗与观察。中位随访72.6个月时,意向治疗人群无病生存期风险比为0.97,PD-L1≥50%亚组为0.86,试验因无效提前终止,辅助纳武利尤单抗未改善无病生存。

要点

  • 已切除NSCLC完成标准辅助治疗后,辅助纳武利尤单抗未改善无病生存。
  • 意向治疗人群无病生存HR为0.97,PD-L1≥50%亚组HR为0.86,均未达统计学显著。
  • 试验在75%信息量时因无效提前终止,中位随访72.6个月。

核心结论

  • 在已切除、无EGFR和ALK敏感序列变异的非小细胞肺癌患者中,完成计划辅助化疗和/或放疗后给予辅助纳武利尤单抗,未改善无病生存。

研究设计与样本

  • 研究在美国国家临床试验网络的378个中心开展,患者经筛查试验识别。
  • 已切除肿瘤至少4 cm和/或淋巴结阳性(N1/N2),且为无EGFR和ALK敏感序列变异的腺癌或鳞状细胞癌,完成计划标准辅助治疗后入组。
  • 患者按1:1随机接受纳武利尤单抗480 mg静脉注射每4周一次最长1年,或标准照护观察。
  • 共466例接受纳武利尤单抗(中位年龄66岁,241例[52%]男性),469例接受观察(中位年龄67岁,245例[52%]男性)。

主要发现

  • 试验在75%信息量时因无效提前终止。

关键数值与推荐

  • 共同主要终点为意向治疗人群和肿瘤PD-L1表达至少50%人群的无病生存期。
  • 若相应无病生存期检验达到统计学显著,则进一步分析总生存期。

临床怎么用

  • 对于已切除、无EGFR和ALK敏感序列变异的非小细胞肺癌患者,完成计划辅助化疗和/或放疗后,辅助纳武利尤单抗未显示无病生存获益。

局限性

  • 试验因无效在75%信息量时提前终止,可能影响统计效能。
  • 研究为开放标签设计,观察组为标准照护观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Preoperative and perioperative nivolumab improve event-free survival in resectable non-small cell lung cancer. The role of adjuvant nivolumab after upfront surgery is unknown. OBJECTIVE: To determine whether adjuvant nivolumab improves disease-free survival and overall survival in patients with resected non-small cell lung cancer with any tumor programmed death-ligand 1 (PD-L1) expression and in those with at least 50% PD-L1 expression. DESIGN, SETTING, AND PARTICIPANTS: This open-label, randomized phase 3 study enrolled participants from May 2016 through September 2019, with median follow-up of 72.6 months at the data cutoff in December 2025. The study was conducted at 378 centers in the US National Clinical Trials Network. Patients were identified through a screening trial. Those with resected tumors at least 4 cm and/or who were lymph node positive (N1/N2) were eligible for inclusion after completion of planned standard adjuvant therapy if the tumor was adenocarcinoma without sensitizing sequence variants in EGFR and ALK or squamous cell carcinoma. INTERVENTION: Patients were randomized in a 1:1 ratio to receive nivolumab 480 mg intravenously every 4 weeks for up to 1 year or standard care observation. MAIN OUTCOMES AND MEASURES: Co-primary end points were disease-free survival in the intention-to-treat population and in those with tumoral PD-L1 expression at least 50%. Overall survival was examined if the corresponding test of disease-free survival was statistically significant. RESULTS: A total of 466 patients (median age, 66 years; 241 [52%] male) were assigned to receive nivolumab and 469 (median age, 67 years; 245 [52%] male) to undergo standard care observation. The median duration of follow-up was 72.6 months. The trial was stopped for futility at 75% information. In the intention-to-treat population, median disease-free survival was 71.3 months with nivolumab and 68.8 months with observation (hazard ratio for progression or death, 0.97 [97% CI, 0.79-1.20]; [95% CI, 0.81-1.17]; 1-sided P = .39). In the subset of participants with PD-L1 of at least 50%, median disease-free survival was 89.8 months with nivolumab and 78.5 months with observation (hazard ratio for progression or death, 0.86 [98% CI, 0.55-1.34]; [95% CI, 0.59-1.25]; 1-sided P = .22). CONCLUSIONS AND RELEVANCE: Adjuvant nivolumab was not associated with improved disease-free survival in patients with resected non-small cell lung cancer without sensitizing EGFR and ALK alterations when given after planned adjuvant chemotherapy and/or radiotherapy. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT02595944.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Chaft JE, Sun Z, Rudin CM, et al. Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA. 2026. PMID: 42224490. doi:10.1001/jama.2026.8992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。